
Warm nights and ill premature babies?
A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Stankov M, Bruhn M, Hoffmann M, Salam A, Eichmann A, Nehlmeier I, Manthey L, Witte T, Pöhlmann S, Ahrenstorf G, Happle C, Dopfer-Jablonka A, Kalinke U, Behrens G
Sidarous L, Ibrahim M, Elhadidy M, Abouelfetouh A, Saif N, Aboelnaga N, Shehat M, Youssef M, Badr E
Moch J, Kappes J, Jauregui R, Schmaus H, Dietrich M, Thies D, Roesner L, Werfel T, Förster R, von Witzendorff D, Debarry J, Winkelmann M, Oberthür S, Clausen J, Gogol M, Cornberg M, Kraft A, Niehaus C
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
The project investigates immune reactions in viral hepatitis, in particular the role of hepatocytes and myeloid cells. The aim is to understand immune processes in the liver and to develop diagnostic approaches for the clinic.
Together with the Department of Structural Biology at the University of Lübeck, human, strongly neutralizing antibodies against HEV were identified and characterized for the first time. These showed a protective effect in the mouse model and are currently being further developed for clinical application, including mRNA-based application methods.
Monoclonal antibodies are transforming modern medicine. At Helmholtz Infection Medicine at MHH, bringing together TWINCORE and CiiM, advanced technologies and AI drive the development of next-generation human antibodies against major infectious diseases.
Ralf Meister, Bishop of the Evangelical-Lutheran Church of Hanover
“Participation and Resilience at the Interface between Science and Society”
Moritz Gaidt, IMP - Research Institute of Molecular Pathology, Vienna
Marylyn M. Addo - UKE Hamburg

